Literature DB >> 1565469

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

S M Bodner1, J D Minna, S M Jensen, D D'Amico, D Carbone, T Mitsudomi, J Fedorko, D L Buchhagen, M M Nau, A F Gazdar.   

Abstract

We investigated the immunocytochemical staining and immunoblotting characteristics of 33 different p53 mutant proteins identified in lung cancer cell lines (18 small-cell lung cancer and 15 non-small-cell lung cancer) using monoclonal antibodies pAbs 240, 421 and 1801. The p53 mutants studied were representative of those found in lung cancer and included three deletions, four nonsense, seven splicing and 19 missense lesions. Control cell lines included six B-lymphoblastoid cell lines and two lung cancer cell lines without p53 mutations. Immunocytochemistry demonstrated 16 cell lines (48%) with definite overexpression of p53 protein (the high-expresser group of mutants), while in the remainder of cases either no p53 expression or low levels of p53 protein expression were found (the low-expresser group of mutants). The type of p53 mutation correlated with the expresser group. High expressers all had p53 missense mutations in exons 5-8, and immunocytochemistry identified 16/17 (94%) of these mutants. Several classes of p53 mutations occur in the low-expresser groups: deletions, splicing mutants, nonsense mutants and missense mutations outside of exons 5-8 all resulted in very low or undetectable levels of p53 protein. We conclude that there are low- and high-expression groups of p53 mutants in lung cancer and that the detection of protein expression in tumor cells by immunocytochemistry and immunoblotting is dependent upon the type of mutation of the p53 tumor-suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565469

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

2.  Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.

Authors:  H Hayashi; H Miyamoto; T Ito; Y Kameda; N Nakamura; Y Kubota; H Kitamura
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage.

Authors:  D Guinee; M Fleming; T Hayashi; M Woodward; J Zhang; J Walls; M Koss; V Ferrans; W Travis
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

4.  Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.

Authors:  Karina J Matissek; Abood Okal; Mohanad Mossalam; Carol S Lim
Journal:  Pharm Res       Date:  2014-03-15       Impact factor: 4.200

5.  Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.

Authors:  Akira Nakamizo; Takanori Inamura; Kiyonobu Ikezaki; Koji Yoshimoto; Satoshi Inoha; Masahiro Mizoguchi; Toshiyuki Amano; Masashi Fukui
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

6.  p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.

Authors:  B G Schneider; S G Hilsenbeck; C H Hensel; V Pekkel; C H Shelton; H A Rodríguez-Martínez; M E Gutiérrez-Díaz; D R Pulitzer; D C Allred
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma.

Authors:  E Cesarman; G Inghirami; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma.

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo; Cláudia Regina G C M de Oliveira; Renée Zon Filippi; André Mathias Baptista; Marcelo Tadeu Caiero
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

10.  cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.

Authors:  Malgorzata Szybka; Magdalena Zakrzewska; Piotr Rieske; Grazyna Pasz-Walczak; Dominika Kulczycka-Wojdala; Izabela Zawlik; Robert Stawski; Dorota Jesionek-Kupnicka; Pawel P Liberski; Radzislaw Kordek
Journal:  BMC Cancer       Date:  2009-08-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.